新型冠狀病毒

Pfizer’s Covid vaccine revenues hit $3.5bn in first quarter

US pharma group sharply raises guidance after signing contracts for 1.6bn doses this year

Pfizer sharply lifted sales forecasts for its Covid-19 vaccine, raising full-year revenue projections for the jab from $15bn to $26bn after reporting a $3.5bn contribution in the first quarter.

The US pharmaceutical group, which splits profits from the vaccine with its German development partner BioNTech, lifted its overall 2021 revenue guidance on Tuesday from $61.4bn to up to $72.5bn, mainly because of contracts signed for the delivery of 1.6bn doses in 2021.

First-quarter revenues of $14.6bn were up 45 per cent on the same period last year and ahead of analysts’ forecasts of $13.7bn. Diluted earnings per share hit 86 cents.

您已閱讀18%(632字),剩餘82%(2891字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×